John Murphy (@JAMurphy_III) profile picture

President & CEO @accessiblemeds

Washington, D.C.
Joined June 2010
Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)Photo by John Murphy (@JAMurphy_III)
John Murphy retweeted
In 2025, generic & biosimilar medicines accounted for scarcely more than 1% of total spending on healthcare in the U.S. At the same time, these lower-cost prescription options accounted for 89% of ALL prescriptions filled in America. Learn more: accessiblemeds.org/resources…
1
88
John Murphy retweeted
While celebrating the near half-trillion dollars in US savings achieved by using generics and biosimilars in 2025, the AAM’s latest report also warned that the sustainability of the generics industry was “in peril” as structural deflation risked causing the sector to “shrink beyond repair.” READ MORE on our newest Savings Report from Dave Wallace for Citeline: insights.citeline.com/generi… @BiosimsCouncil
2
3
1
3
636
John Murphy retweeted
“AAM’s warnings build on years of messaging from the trade group, which in 2023 argued that a “race to the bottom” raised questions about the generic market’s long-term viability and that the biosimilar sector was facing its own sustainability challenges in parallel. AAM voiced similar concerns in 2024 and 2025.” READ MORE from Nick Paul Taylor for @biospace : biospace.com/drug-delivery/a… @BiosimsCouncil
3
3
267
JUST RELEASED in a @WSJ exclusive, our 2026 savings report shows patent litigation as more complex in the U.S., which negatively impacts patient access. The bottom line: Patent abuse in the U.S. must be stopped! Patent litigation in the U.S. is far different—and more complex—than other countries. This complex litigation delays patient access to lower-cost products. As a result, patients and taxpayers pay more—for a longer duration of time. Policymakers must work to limit the number of patents brand-drug manufacturers can assert and prevent anticompetitive practices that delay patient access to biosimilars. View our full Press Release: biosimilarscouncil.org/news/… @WSJhealth @AccessibleMeds
1
3
180
John Murphy retweeted
Big Pharma Exploits the Patent System to Increase Profits. This patent abuse delays market entry for lower-cost generic medicines and keeps drug prices out of reach for Americans. More: accessiblemeds.org
1
1
2
332
John Murphy retweeted
AAM member company, Sandoz, recently brought together industry leaders and U.S. policymakers for an @axios roundtable event. There, Sandoz CEO, Richard Saynor, offered keen insights, including that "biosimilars could be a significant savings opportunity for patients and payers in America." Read more about the roundtable event: axios.com/2026/07/24/axios-l… @BiosimsCouncil
1
7
179
John Murphy retweeted
Alongside our @Biosimscouncil, AAM thanked the Senate HELP Committee this week, for marking up and passing the Expedited Access to Biosimilars Act. This legislation will codify FDA's science-based approach to biosimilar review by limiting comparative efficacy studies. AAM and the Biosimilars Council have long called for clarifications in the current guidance and seek faster, more efficient comparative methods. The Expedited Access to Biosimilars Act will reduce the costs and risks of biosimilar development and encourage industry investment in biosimilars. Similar legislation was passed by the House Energy and Commerce Committee this week, sponsored by Congressman Nick Langworthy (NY-23) and Congresswoman Kim Schrier, M.D. (WA-08). The Expedited Access to Biosimilars Act is now ready for a vote in the full Senate as well as the full House of Representatives.
1
1
4
295
John Murphy retweeted
And that's a wrap! 🎉 Thank you to our AAM event planning team, all attendees, every dedicated sponsor and the speakers, panelists and moderators who truly are the future of generic and biosimilar medicines. YOU are driving what's next for the generic and biosimilar medicines industry—and we are thrilled to see the positive impact we can bring to America's patients when we all work together toward better access to lower-cost prescription medicines. Thanks again for joining us in sunny South Florida! ☀️ Get home safely, everyone!
2
3
113
John Murphy retweeted
More exciting news today, for our member company Lupin Pharmaceuticals, with CEO Vinita Gupta being named to the CNBC's Changemakers list of Women Transforming Business. Congrats, Vinita! cnbc.com/vinita-gupta-2026-c…
With thanks to Keren Haruvi for her dedication and success as former AAM Board Chair, we are now thrilled to welcome Bob Hoffman of @LupinGlobal – as our new Chairman of the AAM Board of Directors! Bob most recently served as Vice-Chair with our AAM board, and we are greatly looking forward to all the future holds under his leadership. Congrats to you, Bob!
1
1
121
John Murphy retweeted
Huge thank you to Joseph M. Shields, Esq, Chief Executive Officer, @transparency_rx and Matt Wetzel, JD, Partner, Goodwin Procter LLP for another invigorating panel discussion. Keeping in-line with the "future" theme for #Access2026, and moderated by AAM's @JAMurphy_III, the discussion offered an overview and implications of the Consolidated Appropriations Act of 2026.
1
1
79
John Murphy retweeted
And the #Access2026 Lifetime Achievement Award goes to… Scott Cornwell, CEO, @DispensaryHope. Congratulations Scott. SO WELL DESERVED! 👏
2
1
84
John Murphy retweeted
We’d also like to extend gratitude for Punit Patel of Zydus Pharmaceuticals, who has stepped into the role of Vice Chair for our association’s board!
With thanks to Keren Haruvi for her dedication and success as former AAM Board Chair, we are now thrilled to welcome Bob Hoffman of @LupinGlobal – as our new Chairman of the AAM Board of Directors! Bob most recently served as Vice-Chair with our AAM board, and we are greatly looking forward to all the future holds under his leadership. Congrats to you, Bob!
2
2
143
John Murphy retweeted
With thanks to Keren Haruvi for her dedication and success as former AAM Board Chair, we are now thrilled to welcome Bob Hoffman of @LupinGlobal – as our new Chairman of the AAM Board of Directors! Bob most recently served as Vice-Chair with our AAM board, and we are greatly looking forward to all the future holds under his leadership. Congrats to you, Bob!
2
2
1
2
457
John Murphy retweeted
👏 What an incredible close to our day one main-stage activity, here at #Access2026! Attendees were on the edge of their seats as top analysts weighed in on the economic and investment climate impacting medicines. A giant thank you to Andy Bressler, MBA of @BankofAmerica, Michael DiFiore, PharmD, MBA of Evercore, Ipsita Smolinski, MBA of Capitol Street and moderator Jayson Slotnik, JD, MPH of Health Policy Strategies. Make sure to join us back on all AAM social channels tomorrow – as Access! 2026 continues from bright and beautiful Aventura, Florida!
2
1
98
John Murphy retweeted
With more than 180 million Americans receiving health benefits through their job, employers are uniquely impacted by the market for pharmacy benefit (PBM) services; and employers are also among those most strongly advocating for reform. Our #Access2026 Fireside Chat with @JamesGelfand just wrapped, and explored employers’ efforts to address PBM business practices and what comes next in the debate over PBMs and their role in our healthcare system. Big thanks to James Gelfand, JD, President and CEO, The ERISA Industry Committee (ERIC) and Executive Director, @BiosimsCouncil and Senior Vice President, Policy, AAM, Alex Keeton, for this essential discussion.
2
2
146
John Murphy retweeted
And that's a wrap for our first panel discussion of the day: “Navigating the Current Political Landscape: Implications for Generic and Biosimilar Policy.” A big thank you to @MsCEAntelo, Esq, Founding Principal and Chief Executive Officer, @FeroxStrategies, Kate Hull, Senior Vice President, Fierce Government Relations and our own Senior Vice President, Government Affairs, AAM, Mark Ratner – who moderated this morning's discussion.
2
2
73